Aktis Oncology, Inc. (AKTS) Stock Price & Analysis
Aktis Oncology, Inc. (AKTS) closed at USD 16.85 on Thursday, October 29, 2026, up 0.18% on the day. The US market is currently closed (after-hours); this is not a live price.
The prior close was USD 16.82; the Oct 29, 2026 session ranged USD 16.61–17.33 on volume of 245,680 shares. Market capitalization is $937.19M, with a 52-week range of USD 14.72–34.19 (NMS). Source: Nexqual, retrieved October 29, 2026 at 23:43 UTC.
Also available as compact Markdown for AI agents: nexqual.com/AKTS.md
Key facts (AKTS)
- 1 of 80 tracked superinvestors hold AKTS (13F, Q2 2026): 1 new, 0 added, 0 reduced, 0 unchanged.
- Analysts: Buy (mean 1.90 on a 1–5 scale) (10 analysts), mean target USD 35.88 (range 33–40).
- Total return with dividends: 1Y -24.8% vs S&P 500 +14.4%; 5Y -24.8% vs S&P 500 +79.1%.
- Next earnings: 2026-11-12 (date not yet confirmed by the company), EPS estimate USD -0.45, revenue estimate $2.5M. All companies reporting that day: https://nexqual.com/earnings/2026-11-12
- Dividend: AKTS paid no cash dividend in the last five years.
- Short interest: 26.68% of float (as of 2026-10-15), 8.4 days to cover.
Superinvestors (SEC 13F-HR, Q2 2026) (AKTS)
1 of 80 tracked investors hold AKTS. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Polen Capital | Polen Capital Management | 0.02% | $2.0M | New position |
Analysts (AKTS)
Consensus Buy (mean 1.90 on a 1–5 scale), 10 analysts; mean target USD 35.88 (low 33, high 40).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-02 | Wedbush | Reiterated | Outperform | $35 |
| 2026-09-09 | Oppenheimer | Initiated | Outperform | $40 |
| 2026-08-19 | Wedbush | Initiated | Outperform | $35 |
| 2026-08-19 | BMO Capital | Initiated | Outperform | $37 |
| 2026-07-14 | JP Morgan | Target raised | Overweight | $30 → $33 |
Total return (dividends reinvested) (AKTS)
| 1Y (from 2026-01-09) | 5Y (from 2026-01-05) | |
|---|---|---|
| Total return | -24.8% | -24.8% |
| S&P 500 (SPY) | +14.4% | +79.1% |
| Per year | — | — |
| Volatility (annualized) | 67.6% | 67.8% |
| Max drawdown | -53.3% (Jun 2026→Oct 2026) | -52.6% (Jun 2026→Oct 2026) |
Dividends (AKTS)
AKTS paid no cash dividend in the last five years.
Short interest (AKTS)
4,313,744 shares sold short, 26.68% of the float, as of Oct 15, 2026 (exchange short-interest report, published about twice a month). Prior report (Sep 15, 2026): 3,252,475 shares (+32.6%). Days to cover: 8.4 (short shares ÷ average daily volume).
AKTS earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| — | Quarter ended Jun 30, 2026 | −$0.44 | −$0.43 | Miss −2.3% | — |
| — | Quarter ended Mar 31, 2026 | −$0.38 | −$0.33 | Miss −15.2% | — |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).
AKTS analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-0.45 | $-0.46 | $0.00 | $2.5M | 7 |
| Next quarter (ends Dec 2026) | $-0.46 | $-0.34 | −$0.11 | $2.1M | 6 |
| Current fiscal year (ends Dec 2026) | $-1.68 | $-1.62 | −$0.06 | $10.6M | 8 |
| Next fiscal year (ends Dec 2027) | $-2.14 | $-1.97 | −$0.17 | $10.3M | 8 |
Key Statistics (as of October 29, 2026 at 23:43 UTC)
| Price | USD 16.85 |
|---|---|
| Change | ▲ 0.18% (up) |
| Previous Close | USD 16.82 |
| Open | USD 16.97 |
| Day Range | USD 16.61 – 17.33 |
| 52-Week Range | USD 14.72 – 34.19 |
| Volume | 245,680 shares |
| Market Cap | $937.19M |
| Exchange | NMS |
Technical Analysis (AKTS)
Nexqual's technical model rates AKTS "SELL" based on 1 bullish and 4 bearish signals across 127 daily candles, as of October 29, 2026 at 23:43 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 39.9 (neutral) |
| vs SMA50 | Below (USD 20.73) |
| MACD | -1.15 (negative) |
Analyst Ratings (AKTS)
Wall Street analysts rate AKTS "Buy" based on 10 analysts, with a mean price target of USD 35.88 (range USD 33–40), per Nexqual as of October 29, 2026 at 23:43 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 10 |
| Mean Target | USD 35.88 |
| High Target | USD 40 |
| Low Target | USD 33 |
| Buy / Hold / Sell | 10 / 0 / 0 |
Earnings (AKTS)
| Next Earnings Date | 2026-11-12 |
|---|---|
| EPS Estimate | USD -0.45 |
| Revenue Estimate | $2.45M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.44 vs est -0.43 ▼ miss |
| 2026-03-31 | USD -0.38 vs est -0.33 ▼ miss |
Source: Nexqual, October 29, 2026 at 23:43 UTC.
Financials & Fundamentals (AKTS)
| Total Revenue | $10.06M |
|---|---|
| Revenue Growth (latest quarter, YoY) | +111.40% |
| Gross Margin | +0.00% |
| Operating Margin | -853.99% |
| Profit Margin | +0.00% |
| Debt / Equity | 0.02 |
| Current Ratio | 16.33 |
| Total Cash | $517.32M |
| Total Debt | $11.24M |
Source: Nexqual, October 29, 2026 at 23:43 UTC.
Financial Health Score (AKTS)
Nexqual rates Aktis Oncology, Inc.'s overall financial health "Mixed" across five dimensions, as of October 29, 2026 at 23:43 UTC.
| Growth | Strong — Revenue +111% YoY (latest Q) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $517M cash vs $11M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$75M (TTM) |
| Efficiency | Mixed — No data |
Ownership (AKTS)
| Insider Ownership | +14.05% |
|---|---|
| Institutional Ownership | +73.22% |
| Shares Outstanding | 53.75M |
| Float | 28.59M |
| Short % of Float | +26.68% |
Source: Nexqual, October 29, 2026 at 23:43 UTC.
Leadership (AKTS)
Aktis Oncology, Inc. is led by Matthew Roden, President, CEO & Director, per Nexqual as of October 29, 2026 at 23:43 UTC.
| President, CEO & Director | Matthew Roden |
|---|---|
| Co-Founder & Chairman | Todd Foley |
| Chief Scientific Officer | Paul L. Feldman |
| Chief Financial Officer | Kyle D. Kuvalanka |
| Chief Operating Officer | Shulamit Ron-Bigger |
Major Backers & Investors (AKTS)
Notable institutional backers of Aktis Oncology, Inc. include MPM Bioimpact LLC, EcoR1 Capital, LLC, Blue Owl Capital Holdings LP, according to Nexqual as of October 29, 2026 at 23:43 UTC.
Active Investors
| Investor | Stake |
|---|---|
| MPM Bioimpact LLC | 9% |
| EcoR1 Capital, LLC | 8.98% |
| Blue Owl Capital Holdings LP | 5.71% |
| T. Rowe Price | 3.82% |
| Wellington Management | 3.66% |
| RTW Investments LP | 2.96% |
| RA Capital Management, L.P. | 2.45% |
| Jupiter Topco LLC | 2.45% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 4.24% |
| Vanguard Group | 3.81% |
Source: Nexqual, October 29, 2026 at 23:43 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| LGND | Ligand Pharmaceuticals Incorpor | USD 317.33 | ▼ 0.45% |
| ORKA | Oruka Therapeutics, Inc. | USD 96.65 | ▲ 0.71% |
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 93.07 | ▲ 1.2% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.39 | ▼ 1.14% |
| AXSM | Axsome Therapeutics, Inc. | USD 143.45 | ▼ 0.04% |
| ABVX | Abivax SA | USD 89.06 | ▼ 0.87% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 29, 2026 at 23:43 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt